Suppr超能文献

中国农村高危人群内镜筛查食管癌的费用估算:一项基于人群的随机对照试验结果。

Estimation of Cost for Endoscopic Screening for Esophageal Cancer in a High-Risk Population in Rural China: Results from a Population-Level Randomized Controlled Trial.

机构信息

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Genetics, Peking University Cancer Hospital and Institute, No. 52 Fucheng Rd, Beijing, 100142, People's Republic of China.

Anyang Cancer Hospital, Anyang, Henan Province, People's Republic of China.

出版信息

Pharmacoeconomics. 2019 Jun;37(6):819-827. doi: 10.1007/s40273-019-00766-9.

Abstract

BACKGROUND AND OBJECTIVE

Population-level endoscopic screening for esophageal cancer has been conducted in China for years. In this study, we aim to provide an updated and precise cost estimation for esophageal cancer screening based on a randomized controlled trial in a high-risk area in China.

METHODS

We estimated the cost of esophageal cancer screening with chromoendoscopy using a micro-costing approach based on primary data of the ESECC (Endoscopic Screening for Esophageal Cancer in China) randomized controlled trial (NCT01688908) from a health sector perspective. Unit costs and quantities of resources were collected to obtain annual screening costs. The screening project was then theoretically expanded to a 10-year period to explore long-term trends of costs. Costs were adjusted to US dollars for the year 2018.

RESULTS

In the ESECC trial, screening cost per endoscopy with a valid pathologic diagnosis was $196, accounting for 3.82% of the gross domestic product per capita in Hua County, and the costs for detecting one esophageal cancer and one early-stage esophageal cancer were $26,347 and $37,687, respectively. In conventional screening in which protocol-driven costs were excluded, costs as above were $134, $18,074, and $25,853. The cost for detecting one gastric cardia cancer or stomach cancer was nine times higher than detecting one esophageal cancer owing to low prevalences of the two cancers. In a simulated 10-year screening project, annual cost decreased notably over time.

CONCLUSIONS

Despite the relatively low absolute cost, population-level endoscopic screening will still be a heavy burden on local government considering the socioeconomic conditions. Long-lasting programs would be less costly and population-level screening would make little sense in non-high-risk regions.

摘要

背景与目的

中国多年来一直在进行基于人群的食管癌内镜筛查。本研究旨在基于中国高危地区的一项随机对照试验,为食管癌筛查提供最新且准确的成本估算。

方法

我们采用微观成本法,基于 ESECC(中国食管癌内镜筛查)随机对照试验(NCT01688908)的原始数据,从卫生部门的角度来估计使用染色内镜进行食管癌筛查的成本。收集单位成本和资源数量,以获得年度筛查成本。然后,将筛查项目理论上扩展到 10 年,以探索成本的长期趋势。将成本调整为 2018 年的美元。

结果

在 ESECC 试验中,每例有有效病理诊断的内镜筛查成本为 196 美元,占华县人均国内生产总值的 3.82%,发现 1 例食管癌和 1 例早期食管癌的成本分别为 26347 美元和 37687 美元。在排除方案驱动成本的常规筛查中,上述成本分别为 134 美元、18074 美元和 25853 美元。由于两种癌症的患病率较低,发现 1 例贲门癌或胃癌的成本是发现 1 例食管癌的 9 倍。在模拟的 10 年筛查项目中,年度成本随时间显著下降。

结论

尽管绝对成本相对较低,但考虑到社会经济状况,人群层面的内镜筛查仍将给地方政府带来沉重负担。持久的项目成本较低,而非高危地区进行人群层面的筛查意义不大。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验